Cargando…
Screening of Neonatal UK Dried Blood Spots Using a Duplex SMN1 Screening Assay
Spinal muscular atrophy (SMA) is an autosomal inherited neuromuscular genetic disease caused, in 95% of cases, by homozygous deletions involving the SMN1 gene exon 7. It remains the leading cause of death in children under 2 years of age. New treatments have been developed and adopted for use in man...
Autores principales: | Adams, Stuart P., Gravett, Emma, Kent, Natalie, Kricke, Susanne, Ifederu, Adeboye, Scoto, Mariacristina, Samsuddin, Salma, Muntoni, Francesco |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8629004/ https://www.ncbi.nlm.nih.gov/pubmed/34842601 http://dx.doi.org/10.3390/ijns7040069 |
Ejemplares similares
-
Defining the Newborn Blood Spot Screening Reference Interval for TSH: Impact of Ethnicity
por: Peters, Catherine, et al.
Publicado: (2016) -
Drug screening with human SMN2 reporter identifies SMN protein stabilizers to correct SMA pathology
por: Wang, Yiran, et al.
Publicado: (2019) -
Revised Hammersmith Scale for spinal muscular atrophy: Inter and intra-rater reliability and agreement
por: Ramsey, Danielle, et al.
Publicado: (2022) -
Assessment of Spinal Muscular Atrophy Carrier Status by Determining SMN1 Copy Number Using Dried Blood Spots
por: Wijaya, Yogik Onky Silvana, et al.
Publicado: (2020) -
Influence of Hematocrit and Total-Spot Volume on Performance Characteristics of Dried Blood Spots for Newborn Screening
por: Hall, Elizabeth M., et al.
Publicado: (2015)